Among those celebrating today’s agreement on a voluntary rebate scheme for branded medicines in the UK, there are dissenting voices, including a group representing manufac
After months of wrangling, an agreement has finally been reached on a successor to the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), the system of reve
As a successor to the 2019 Voluntary Scheme for Branded Medicines Access and Pricing is being negotiated, Leela Barham asks where rebates should go in future - that is, if rebates remain at
The FDA is asking digital health technology developers to come up with a solution to measuring a common symptom of Parkinson’s disease that can have a serious impact on pa
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.